From October 12th to 15th, 2025, the 10th Expand North Star was held as scheduled in Dubai Harbor. Inspire Technologies showcased its innovative liver health solutions, showcasing its latest developments in liver disease diagnosis and treatment. During the exhibition, the team engaged with clients and industry partners from around the world, exploring new avenues for future collaboration and development opportunities based on current innovation trends in the healthcare field.
Expand North Star is the world’s largest startup event, bringing together the world’s top innovators, investors, and industry leaders. Focusing on cutting-edge fields such as artificial intelligence, clean energy, Web3, climate technology, and fintech, the event has attracted over 2,000 startups and has become a vital platform for businesses to collaborate across regions and explore new opportunities.
During the exhibition, the Eieling booth attracted significant attention from attendees, fully demonstrating the industry’s high recognition of the company’s technological strength and market prospects. Visitors expressed a strong interest in Eieling Technology’s independently developed innovative products, the Liverscan® Portable Liver Elastography Ultrasound Diagnostic System (FDA 510K) and the FattaLab® Fatty Liver Diagnostic—
and engaged in in-depth discussions on their technical principles and application scenarios.
Through detailed product demonstrations and technical explanations, the team fully demonstrated the company’s cutting-edge solutions in the field of liver health. At the same time, Eieling and potential partners discussed hot topics such as global trends in early liver screening, technological advancements, and market opportunities.
Adapt to the AI wave and seize development opportunities
The increasing prevalence of obesity, the increasing pressure on medical institutions to diagnose and treat patients, and the uneven distribution of medical resources are driving the need for more efficient and accessible liver screening methods. Eieling Technology’s flagship products, Liverscan® and FattaLab®, leverage their unique technological advantages and clinical value to provide efficient and convenient solutions for liver health.
Liverscan® utilizes the world’s exclusive patented technology for real-time B-mode ultrasound-guided transient elastography to provide healthcare professionals with visual guidance for liver screening. Its wireless and portable nature allows for flexible liver screening in diverse scenarios, contributing to improved global early screening efficiency for liver disease. Furthermore, Liverscan® effectively addresses the challenges of detecting patients with abdominal obesity and a high BMI, significantly improving screening reliability and accuracy, and providing solid technical support for the early diagnosis and treatment of liver fibrosis and fatty liver disease.
FattaLab® is optimized for portability and lightweight design, making it more practical and user-friendly. With one-click detection and automated analysis, quantitative liver fat data can be obtained in just 30 seconds. The device utilizes a proprietary, patented Auto Intra-Focus Fusion human liver fat detection algorithm, which automatically identifies liver regions and effectively reduces operational barriers and human error. FattaLab® is widely applicable in diverse scenarios and is poised to accelerate the advancement of fatty liver screening and weight management in the general population.
This exhibition further deepened the company’s exchanges and collaborations with the Middle East and global markets. Leveraging the research strengths of the Hong Kong Polytechnic University, Eieling Technology will continue to optimize the technical performance and practical applications of Liverscan® and FattaLab®, effectively addressing the practical challenges of non-invasive liver screening. Going forward, Eieling Technology will continue to enhance its innovation capabilities, promote multi-dimensional and in-depth collaborations with businesses, and contribute to the universalization and precision of global liver health management.